Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 4/20 | 0.57 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.49 |
| ▸ | CTSC | P53634 | 2/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2520131 | 0.94 | CTSD (0.59) | CTSDCTSBCTSC | |
| SCHEMBL2520136 | 0.94 | CTSD (0.59) | CTSDCTSBCTSC | |
| SCHEMBL29658166 | 0.91 | MME (0.60) | CTSDCTSBPSMB5CTSCMME | |
| SCHEMBL31074731 | 0.90 | OPRD1 (0.49) | CTSDMME | |
| SCHEMBL30582928 | 0.90 | OPRD1 (0.49) | CTSDMME | |
| SCHEMBL30193614 | 0.89 | OPRD1 (0.56) | CTSDCTSB | |
| SCHEMBL11059164 | 0.89 | CTSD (0.59) | CTSDPSMB5MME | |
| SCHEMBL11059196 | 0.89 | CTSD (0.59) | CTSDPSMB5MME | |
| SCHEMBL30350060 | 0.89 | CTSD (0.57) | CTSD | |
| SCHEMBL17770758 | 0.87 | CTSD (0.68) | CTSDPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | CTSD 503/4885CTSB 1507/4885PSMB5 3664/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | CTSD 213/4885CTSB 104/4885PSMB5 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.